Tumor suppressor genes (TSG)

Anticancer Research

Volumn 19, Issue 6 A, 1999, Pages 4715-4728

  Teh, Bin Than ^a,b   Larsson, Catharina ^a   Nordenskjöld, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Tumor suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RESEARCH; FAMILIAL CANCER; HUMAN; INFORMATION SCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 0033388806     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Thomlinson IPM, Novelli MR, Bodmer WF, The mutation rate and cancer. Proc Natl Acad Sci USA. 93: 14800-14803, 1996.
2. Posadas EM, Criley SR, Coffey DS: Chaotic oscillations in cultured cells: Rat prostate cancer. Cancer Res 56: 3682-3688, 1996.
3. Loeh LA: Mutator phenotype may be required for multistage carcinogencsis. 51: 3075-3079, 1991.
4. Malins D, Polissar NL, Schaefer S, Su Y, Vinson M: A unified theory of carcinogenesis based on order-disorder transitions in DNA structure as studied in the human ovary and breast. Proc Natl Acad Sci USA 95: 7637-7642, 1998.
5. Boveri T: Zur Frage der Entstehung maligner Tumoren. Jena: Verlag von Gusta Fisher 1914.
6. Harris H, Miller OJ, Klein G, Worst P, Tachihana T: Suppression of malignancy by cell fusion. Nature 223: 363-368, 1969.
7. Knudson AG: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
8. Friends SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to rctinoblastoma and osteosarcoma. Nature 323: 643-646, 1986.
9. Lee W-H, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY-HP: Human rctinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399, 1987.
10. Fung Y-KT, Murphree LA, T'Ang T, Qian J, Hinrichs SH, Benedict WF: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236: 1657-1661, 1987.
11. Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Boostein R, Friedmann T, Lee EY-HP, Lee W-H: Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science 242: 1563-1566, 1988.
12. Haber D, Harlow E: Tumour-suppressor genes evolving definitions in the genomic age. Nature Genet 16: 320-322, 1997.
13. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature 392: 402-405, 1998.
14. Kinzler KW, Vogelstein B: Gatekeepers and caretakers. Nature 386: 761-763, 1997.
15. Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 280: 1036-1037, 1998.
16. Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IPM, Houslton RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA: Mutations in the SMAD4/DPC4 in juvenile polyposis. Science 280: 1086-1088, 1998.
17. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180, 1998.
18. Tang B, Bötlinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM: Transforming gorwth factor-B1 is a new form of tumor suppressor with true haploid insufficiency. Nature Med 4: 802-806, 1998.
19. Herskowitz I: Functional inactivation of genes by dominant negative mutations. Nature 329: 219-222, 1987.
20. Dragani TA, Canzian F, Pierotti MA: A polygenic model of inherited predisposition to cancer. FASEB J 10: 865-870, 1996.
21. Eng C: The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprungs disease. N Engl J Med 335: 943-951, 1996.
22. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis TJ, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui L, Ceil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch J, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B: Germline and somatic mutations in the tyrosine kinase domain of the Met protooncogene in papillary renal carcinomas. Nature Genet 16: 68-73, 1997.
23. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H, Kitamura Y, Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 19:323-324, 1998.
24. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16ink4a binding domain of CDK4 in familial melanoma. Nature Genet 12: 97-99, 1996.
25. Ming JE, Kaupas ME, Roesller E, Brunner HG, Nance WE, Stratton RF, Sujansky E, Bale SJ, Muenke M: Mutations of PATCHED in holoprosencephaly. Am J Hum Genet 63: A27 (Suppl), 1998.
26. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nature Genet 4: 42-46, 1993.
27. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD: An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 95: 5166-5171, 1998.
28. Ben-Ze'ev A: Cytoskeletal and adhesion proteins as tumor suppressors. Curr Opin Cell Biol 9: 99-108, 1997.
29. Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA: Phenotype of mice lacking functional Deleted in colorectal cancer (Dec) gene. Nature 386: 796-804, 1997.
30. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM: Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Ape Genes. Cell 92: 645-656, 1998.
31. Steiner P, Barnes DM, Harris WH, Weinberg RA: Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nature Genet 16: 332-333, 1997.
32. Li L, Li X, Francke U, Cohen SN: The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88: 143-154, 1997. (retracted. Cell 93, 1998)
33. Ackerknecht EH: History and geography of the most important diseases. New York, Hafner, 1965.
34. Mulvihill JJ, Miller RW, Fraumeni JF (eds): Genetics of human cancer. New York, Raven Press, 1977.
35. de Mars R: 23rd Annual Symp. Fundamental Cancer Research 1969. (Williams & Wilkings), p.105, 1970.
36. Gorlin RJ: Nevoid basal cell carcinoma syndrome. Dermatol Clin 13: 113-125, 1995.
37. Den Otter W, Koten JW, van der Vegt BJH, Beemer FA, Boxma OJ, de Graaf PW, Derkinderen DJ, Hill FWG, Huber J, Klein WR, Lips CJM, Mckenzie RL, Roholl PJM, Sluijter FJH, Tan KEWP, van der Heyden KA; van der Yen L, van Unnik JAM: Oncogenesis by mutations in anti-oncogenes: a view. Anticancer Res 10: 475-487, 1990.
38. Menke A, McInne L, Hastie ND, Schedi A: The Wilms' tumor suppressor WT1: Approaches to gene function. Kidney Int 53: 1512-1518, 1998.
39. Chen F, Kishida T, Yao M, Hustad T, Olavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia EY, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mut 5: 66-75, 1995.
40. Otterson GA, Chen W-D, Coxon AB, Khleif SN, Kaye FJ: In complete penetrance of familial retinoblastoma linked to germline mutations that result in partial loss of RB function. Proc Natl Acad Sci USA 94: 12036-12040, 1997.
41. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasms. Science 250; 1233-1238, 1990.
42. Bale AE: Variable expressivity of patched mutations in flies and humans. Am J Hum Genet 60: 10-12, 1997.
43. Bahn RC, Scheithauer BW, van Heerden JA, Laws ER, Horvath E, Gharib H: Nonidentical expressions of multiple endocrine neoplasia type I in identical twins. Mayo Clin Proc 61: 689-696, 1986.
44. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Rutledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, Goldgar DE, Narod SA: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 12: 309-311, 1996.
45. Brunei JS, Vesprin D, Abrahamson J, Neuhausen S, Narod SA: Breast cancer risk in BRCA1/BRCA2 carries is modified by the CYP1A1 gene. Am J Hum Genet 63: A47 (Suppl)
46. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W: Genetic identification of Mom-1, a major modifier locus affecting MIN-induced intestinal neoplasia in the mouse. Cell 75: 631-639, 1993.
47. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES : Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nature Genet 17: 88-91, 1997.
48. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F, Lubensky IA, Duan R, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Issacs WB, Lerman MI, Zbar B, Linehan WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 7: 85-90,1994
49. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431, 1991.
50. Futreal P, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett L, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McLure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart J, Marks J, Barrett J, Skolnick M, Kamb A, Wiseman R: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122, 1994.
51. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochrane C, Gumbs C, Seal S, Barfoot R, Collins N, Bignall G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuk A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA: BRCA2 mutations in primary breast and ovarian cancers. Nature Genet 13; 238-240, 1996.
52. Greenblatt MS, Bennett WP, Hollstein M, Harris CC, Mutations in the p53 Tumor Suppressor Gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
53. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
54. Kaelin WG Jr: Another p53 Doppelgänger? Science 281: 57-58, 1998.
55. Knudson AG: Retinohlastoma: a prototypic hereditary' neoplasm. Semin Oncol 5: 57-60, 1978.
56. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallic BL, Murphree AL, Strong LC, White RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779-784, 1983.
57. Cavenee WK, Hansen MF, Nordenskjold M, Kock E, Maumenec I, Squire JA, Phillips RA, Gallie BL: Genetic origin of mutations predisposing to retinoblastoma. Science 228: 501-503, 1985.
58. Spirio LN, Samowitz W, Robertson J, Robertson M, Burt RW, Leppert M, White R: Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nature Genet 20: 385-388, 1998.
59. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996.
60. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER: Somatic inactivation of the VHL gene in Von Hippel-Lindau Disease. Am J Hum Genet 60: 765-771, 1997.
61. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates lumour development in heterozygous but not nullizygous p53-deficienl mice. Nature Genet 9: 305-311, 1995.
62. Hata A, Lo RS, Wotton D, Lagna G, Massague J: Mutations increasing autoinhibilion inactivate tumour suppressors Smad2 and Smad 4. Nature 383: 82-87, 1997.
63. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393: 229-234, 1998.
64. Laken SJ, Pctersen CM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winawer S, Of fit K, Luce MC, Kinzler KW, Vogelstein B: Familial colorcctal cancer in Ashkenazi due to a hypermutable tract in APC. Nature Genet 17: 79-83, 1997.
65. Mulligan G, Jacks T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 14: 223-229, 1998.
66. Levine AJ: P53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
67. Moon RT, Miller JR: The APC tumor suppressor protein in development and cancer. Trends Genet 13: 256-258, 1997.
68. Behrens, J, Jerchow B-A, Wurtele M, Ashrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W: Functional interaction of an axin homolog, conductin, with of b-catenin, APC and GSK3b. Science 280: 596-599, 1998.
69. Morin PJ, Vogelstein B, Kinzler KW: Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 93: 7950-7954, 1996.
70. Korinek V, Baker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clovers H: Constitutive transcriptional activation by a b-Catenin-Tcf complex in APC-/-colon carcinoma. Science 275: 1784-1787, 1997
71. He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da C'osta LT, Morin PJ, Vogelstcin B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. 1998.
72. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garret KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcription elongation hy the VHL tumor suppressor protein. Science 269: 1402-1406, 1995.
73. Pause A, Lee S, Worrell RA, Chen DYT, Burgess WH, Linehan WM, Klausner RD: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997.
74. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O, The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968, 1998.
75. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma hy blocking protein kinase C pathways. J Biol Chem 272: 27509-27512, 1997.
76. Hahn H, Wicking C, Zaphiropoulous PC, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R. Chenevix-Trench G, Wainwright B, Bale AE: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85: 841-851, 1996.
77. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, Quinn AC, Myers RM, Cox DR, Epstein EH Jr, Scott MP: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272: 1668-1671, 1996.
78. Eng C: Genetics of Cowden-syndrome - through the looking glass of oncology. Int J Oncol 12: 701-710, 1998.
79. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. Science 280: 1614-1617, 1998.
80. TSC1 consortium: Identification of the tuberous sclerosis gene TSCI on chromosome 9q34. Science 277: 805-808, 1997.
81. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75: 1305-1315, 1993.
82. Soucck T, Pusch O, Wienccke R, Declue JE, Hengstschlager M: Role of the tuberous sclerosis gene-2 product in cell cycle control - loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 272: 29301-29308, 1997.
83. van Slegtenhorst M, Nellis M, Nagelkerken B, Cheadle J, Snell R, van den Ouwcland, Reuser A, Sampson J, A. Halley D, van der Sluijs: Interaction between hamartin and tuberin, the TSCI and TSC2 gene products. Hum Mol Genet 7: 1053-1057, 1998.
84. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F: The NF1 locus encodes a protein functionally related to mammalian GAP and IRA proteins. Cell 63: 851-859, 1990.
85. Basu TN, Gutmann DH, Fletcher A, Glover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumor cells from type I neurofibromatosis patients. Nature 356: 713-715, 1992.
86. Trofatter JA, MacCollin MM, Rutter JL, Murrel JR, Duyao MP, Parry DM, Eldridge R, Kiev N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short P, Buckler AJ, Gusclla JF: A novel Moesin-, Ezrin, Radisin-like gene is a candidate for the Neurofibromatosis 2 tumor suppressor. Cell 72: 791-800, 1993.
87. Rouleau GA, Merel P, Lutchman M, Sanson M, Zueman J, Marineau C, Hong-Xuan K, Demzuck S, Desmaze C, Plougastel B, Pulst S, Lenoir G, Bijlsma E, Fashold R, Dumanski JP, Dejong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G: Alteration in a new gene encoding a putative membrane organizing protein causes Neurofibromatosis type 2. Nature 363: 515-521, 1993.
88. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT: Decreased expression of BRCAI accelerates growth and is often present during sporadic breast cancer progression. Nature Genet 9: 444-450, 1995.
89. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCAI with Rad 51 in mitotic and meiotic cells. Cell 88: 265-275, 1997.
90. Patel KJ, Yu VPCC, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BAJ, Venkitaraman AR: Involvement of Brca2 in DNA repair. Cell 1: 347-357, 1998.
91. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA: BRCAI required for transcription-coupled repair of oxidative DNA damage. Science 281: 1009-1012, 1998.
92. Larson JS, Tonkinson JL, Lai MT: A BRCAI mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 57: 3351-3355, 1997.
93. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS: Arrest of the cell cycle by the tumour-suppressor BRCAI requires the CDK-inhibitor p21 WAFl/Cipl. Nature 389: 187-190, 1997.
94. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS: BRCAI physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721, 1998.
95. Habibur S, Zhou J-P, Rao VN, Reddy ESP: The BRCA2 is a histone acetyltransferase. Oncogene 16: 2283-2285, 1998.
96. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Teo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.I. Science 277: 350-353, 1996.
97. Wrana JL, Attisano L: MAD-related proteins in TGF-B signalling. Trends Genet 12: 493-496, 1996.
98. Ilyas M, Tomlinson IP: The interactions of ARC, E-cadherin and heta-catenin in tumour development and progression. J Pathol 182: 128-137, 1997.
99. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 12: 97-99, 1996.
100. Teh BT: Recent advances in multiple endocrine neoplasia type I. Curr Opin Endocrinol Diabetes 5: 35-39, 1998.
101. Argawal SK, Yuru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Lee Burns A: Menin interacts with the API transcription factor Jun D and represses Jun D-activated transcription. Cell 96: 143-152, 1999.
102. Hemminki A, Tomlinson I, Markie D, Jarvinen H, Sistonen P, Bjorkqvist AM, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen LA: Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nature Genet 15: 87-90, 1997.
103. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184-187, 1998.
104. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genet 18: 38-43, 1998.
105. Bugert P, Kovacs G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 149: 2081-2088, 1996.
106. Dowell SP, Hall PA: The clinical relevance of the p53 tumour suppressor gene. Cytopathol 5: 133-145, 1994.
107. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
108. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an EIB gene-atenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3: 639-645, 1997.